XML 61 R29.htm IDEA: XBRL DOCUMENT
v3.19.1

Revenues Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2019
Revenue from Contract with Customer [Abstract] |
Revenues by product | Revenues by product are summarized as follows:
| For the Three Months Ended March 31,
(In millions) | 2019 |  | 2018
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 717.7 |  |  | $ | 281.1 |  |  | $ | 998.8 |  |  | $ | 728.9 |  |  | $ | 258.0 |  |  | $ | 986.9 |
Interferon* | 327.3 |  |  | 173.6 |  |  | 500.9 |  |  | 371.4 |  |  | 178.9 |  |  | 550.3 |
TYSABRI | 245.0 |  |  | 215.4 |  |  | 460.4 |  |  | 249.7 |  |  | 212.4 |  |  | 462.1 |
FAMPYRA | — |  |  | 22.9 |  |  | 22.9 |  |  | — |  |  | 24.4 |  |  | 24.4 |
ZINBRYTA | — |  |  | — |  |  | — |  |  | — |  |  | 1.4 |  |  | 1.4 |
Subtotal: MS product revenues | 1,290.0 |  |  | 693.0 |  |  | 1,983.0 |  |  | 1,350.0 |  |  | 675.1 |  |  | 2,025.1 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 223.3 |  |  | 295.2 |  |  | 518.5 |  |  | 188.0 |  |  | 175.9 |  |  | 363.9 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |
BENEPALI | — |  |  | 124.0 |  |  | 124.0 |  |  | — |  |  | 120.9 |  |  | 120.9 |
FLIXABI | — |  |  | 14.7 |  |  | 14.7 |  |  | — |  |  | 6.6 |  |  | 6.6 |
IMRALDI | — |  |  | 35.7 |  |  | 35.7 |  |  | — |  |  | — |  |  | — |
Subtotal: Biosimilar product revenues | — |  |  | 174.4 |  |  | 174.4 |  |  | — |  |  | 127.5 |  |  | 127.5 |
Other: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 4.1 |  |  | 4.1 |  |  | — |  |  | 7.0 |  |  | 7.0 |
Total product revenues | $ | 1,513.3 |  |  | $ | 1,166.7 |  |  | $ | 2,680.0 |  |  | $ | 1,538.0 |  |  | $ | 985.5 |  |  | $ | 2,523.5 |
*Interferon includes AVONEX and PLEGRIDY.
Analysis of change In reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, as of December 31, 2018 | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
Current provisions relating to sales in current year | 141.2 |  |  | 680.3 |  |  | 4.7 |  |  | 826.2 |
Adjustments relating to prior years | 0.3 |  |  | (25.1 | ) |  | 0.3 |  |  | (24.5 | )
Payments/credits relating to sales in current year | (60.8 | ) |  | (233.9 | ) |  | (0.1 | ) |  | (294.8 | )
Payments/credits relating to sales in prior years | (92.1 | ) |  | (378.1 | ) |  | (4.6 | ) |  | (474.8 | )
Balance, as of March 31, 2019 | $ | 116.4 |  |  | $ | 932.0 |  |  | $ | 35.0 |  |  | $ | 1,083.4 |
Total reserves included in consolidated balance sheets | The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) | As of March 31, 2019 |  | As of December 31, 2018
Reduction of accounts receivable, net | $ | 175.8 |  |  | $ | 176.6 |
Component of accrued expenses and other | 907.6 |  |  | 874.7 |
Total revenue-related reserves | $ | 1,083.4 |  |  | $ | 1,051.3 |
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Three Months Ended March 31,
(In millions) | 2019 |  | 2018
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA | $ | 390.8 |  |  | $ | 349.6 |
Other revenues from anti-CD20 therapeutic programs | 126.6 |  |  | 93.6 |
Total revenues from anti-CD20 therapeutic programs | $ | 517.4 |  |  | $ | 443.2 |
Other revenues | Other revenues are summarized as follows:
| For the Three Months Ended March 31,
(In millions) | 2019 |  | 2018
Revenues from collaborative and other relationships: |  |  |
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie | $ | (0.4 | ) |  | $ | (4.7 | )
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis | 24.8 |  |  | 17.9 |
Other royalty and corporate revenues: |  |  |
Royalty | 3.9 |  |  | 10.6 |
Other corporate | 264.1 |  |  | 140.6 |
Total other revenues | $ | 292.4 |  |  | $ | 164.4 |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration